Cologne/Berlin, Germany, and Boston, MA,USA, September 01, 2022 – InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced that it has appointed Mrs. Nicole Witzmann as Chief Financial Officer (CFO) effective September 1, 2022.
Mrs. Witzmann looks back on more than eight years of experience in corporate finance in the healthcare industry and joins from Adrenomed AG, where she served several years as Head of Finance. As CFO, Mrs. Witzmann will be responsible for general administration, accounting and controlling, financial reporting, and – together with CEO Dr. Achim Plum – investor relations and fundraising. At present, the Company is preparing a Series B financing round, which is expected to be closed towards the end of 2022 or in early 2023on the back of major value-creating milestones, such as the clinical validation of the HypoxE® biomarker panel that is expected to be finalized in the next weeks.
Mrs. Witzmann will take over from Dr.Andreas Lischka who has headed InfanDx’ finance department as an external advisor since January 2021. While Dr. Lischka will leave the Company on his own request to pursue other opportunities, he will remain available for an extended period to ensure a smooth transition to Mrs. Witzmann.
“We are very pleasedthat Nicole joins our management team,” commented Dr. Achim Plum, CEO of InfanDx.“Hving worked with her for some time in a previous position, I am convincedthat she will add exactly the skills and experience that we need to furtherdevelop InfanDx into a fully integrated diagnostics company providinginnovation for neonatal acute and critical care. I would also like to take theopportunity to wholeheartedly thank Dr. Lischka for his services to InfanDxthat were invaluable in repositioning and growing the Company since I took overas CEO i January 2021.”
“I feel very honored to be part of InfanDx´ management team in the future,” said Nicole Witzmann. “As a mother of three, with my youngest son born only a few months ago, I feel particularly close to InfanDx´ vision and mission. I am excited and eager to help bring the InfanDx HypoxE Test for hypoxic-ischemic encephalopathy to the market as it bears the chance to prevent severe lasting injuries of children affected by oxygen deficit during birth."
For media inquiries, please contact:
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
For further information on InfanDx, please contact:
Nathaly Schaefer, Corporate Affairs Manager
P: +49 (0) 30 556 535 81
InfanDx USA, Inc.
Jordan deVos (VP Operations)